BCIQ Profiles

Company Profile ReportTarget Profile Report
0909 Quick Takes
BioCentury & Getty Images


Sept. 9 Quick Takes: Obsidian readies for IPO with $115M crossover round

Plus: Venture rounds for Lexeo, Evommune, Alamar, and setbacks for Humanigen, Sanofi and more

Sep 10, 2021 | 1:44 AM GMT

Cell and gene therapy play Obsidian Therapeutics Inc. looks set to seek a public listing after raising $115 million in a series B round led by The Column Group Crossover Fund. Other new investors included RA Capital, Surveyor Capital, Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal BioVenture Partners, Samsara BioCapital and Soleus Capital. Existing investors Atlas Venture, Vertex Ventures HC, Amgen Ventures, Bristol Myers Squibb Co. (NYSE:BMY) and Vertex Pharmaceuticals

Read the full 1089 word article

How to gain access

Continue reading with a
two-week free trial.